eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2003
vol. 28
 
Share:
Share:
abstract:

Role of intravenous immunoglobulin preparations (IVIG) in therapy of autoimmune diseases

Piotr Wiland

(Centr Eur J Immunol 2003; 28 (1): 41–45)
Online publish date: 2004/01/20
View full text Get citation
 
Abstract
Indications for application of high doses of intravenous immunoglobulin preparations (intravenous immunoglobulins – IVIG) have been significantly broadened in the recent decade. Results of the recent controlled clinical studies have accentuated a particular therapeutic value of IVIG in Kawasaki syndrome. At present, the treatment of choice for acute Kawasaki syndrome is a single dose of IVIG, at 2 gm/kg administered over 10–12 hours, in combination with acetylsalicylic acid. Literature of last years contains reports of variable effectiveness of IVIG in other autoimmune diseases, like anti-phospholipid syndrome, severe forms of thrombocytopenia in the course of systemic lupus erythematosus, some other severe forms of lupus with multiorgan manifestation, dermatomyositis, polymyositis, juvenile dermatomyositis and inclusion body myositis.
Attempts were made to administer IVIG in the course of lupus nephritis, systemic vasculitis and in the severe form of systemic juvenile arthritis. On the other hand, no favorable effects of IVIG could be demonstrated in rheumatoid arthritis.
keywords:

intravenous immunoglobulins, Kawasaki syndrome, anti-phospholipid syndrome, anti-cardiolipin antibodies, vasculitis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.